Back to top

Image: Shutterstock

Top Ranked Momentum Stocks to Buy for October 6th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 6th:

Quidel Corporation (QDEL - Free Report) : This diagnostic testing solutions developer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days.

Quidel’s shares gained nearly 63% over the last one month compared with the S&P 500’s decline of 0.5%. The company possesses a Momentum Score of A.

Owens & Minor, Inc. (OMI - Free Report) : This healthcare solutions company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 69.4% over the last 60 days.

Owens Minor, Inc. Price and Consensus

Owens  Minor, Inc. Price and Consensus

Owens Minor, Inc. price-consensus-chart | Owens Minor, Inc. Quote

 

Owens & Minor’s shares gained 46.5% over the last one month. The company possesses a Momentum Score of A.

Charles & Colvard, Ltd. (CTHR - Free Report) : This moissanite jewels and finished jewelries manufacturer has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.

Charles & Colvard’s shares gained 30.9% over the last one month. The company possesses a Momentum Score of A.

SYNNEX Corporation (SNX - Free Report) : This business process services provider has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 14% over the last 60 days.

Synnex’s shares gained 20.3% over the last one month. The company possesses a Momentum Score of A.

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>